Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]

Phase 2Terminated

0 views this week 0 watching💤 Quiet

Interest: 27/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Bone Giant Cell Tumor

Conditions

Bone Giant Cell Tumor

Trial Timeline

Sep 26, 2019 → Jul 30, 2020

NCT ID

NCT03620149

About Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]

Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA] is a phase 2 stage product being developed by Amgen for Bone Giant Cell Tumor. The current trial status is terminated. This product is registered under clinical trial identifier NCT03620149. Target conditions include Bone Giant Cell Tumor.

What happened to similar drugs?

16 of 20 similar drugs in Bone Giant Cell Tumor were approved

Approved (16) Terminated (1) Active (4)

✅Reclast (ZOL446, zoledronic acid)NovartisApproved

✅zoledronic acidNovartisApproved

✅Zoledronic acidNovartisApproved

✅Disodium pamidronate + PlaceboNovartisApproved

✅Zoledronic acidNovartisApproved

✅PamidronateNovartisApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03620149	Phase 2	Terminated	Sep 26, 2019	Jul 30, 2020	Bone Giant Cell Tumor
NCT03691311	Phase 1	UNKNOWN	Jul 5, 2018	Feb 5, 2023	Breast Neoplasm Female

Competing Products

20 competing products in Bone Giant Cell Tumor

See all competitors

Product	Company	Stage	Hype Score
Denosumab + Zoledronic Acid	Daiichi Sankyo	Phase 3	40
Enzalutamide	Astellas Pharma	Phase 2	35
Enzalutamide	Astellas Pharma	Phase 2	35
Tacrolimus	Astellas Pharma	Phase 2	35
Tacrolimus	Astellas Pharma	Phase 2	35
Merestinib	Eli Lilly	Phase 1	21
FORTEO + Placebo	Eli Lilly	Phase 1	29
Arzoxifene + Placebo	Eli Lilly	Phase 3	40
Tanezumab	Eli Lilly	Phase 3	40
Anastrozole + Tamoxifen	AstraZeneca	Phase 3	40
zoledronic acid + placebo to zoledronic acid + Risedronate + Placebo to risedronate + Calcium and vitamin D supplements	Novartis	Phase 3	40
Zoledronic acid	Novartis	Phase 3	40
Zoledronic acid + Letrozole	Novartis	Phase 3	40
Zoledronic acid	Novartis	Phase 3	40
Nilotinib	Novartis	Phase 1	29
Reclast (ZOL446, zoledronic acid)	Novartis	Approved	43
Zoledronic acid	Novartis	Phase 3	32
Zoledronic Acid + Risedronate + Placebo to Risedronate + Placebo to Zoledronic Acid	Novartis	Phase 3	40
zoledronic acid	Novartis	Phase 1	29
Ruxolitinib continuous therapy	Novartis	Phase 2	39